4511

Novel, Dual-Specific Anti-Cancer Epigenetic Drugs

Ben-Sasson Shmuel, HUJI, School of Medicine - IMRIC, Developmental Biology and Cancer Research
Tsvelikhovsky Dmitry, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

 

Keywords

Epigenetics, Dual-specificity, Enzymes, anti-cancer

Current Development Stage

TRL3 - Hypothesis testing and initial POC demonstrated

Application

  • Cancer cells lose their epigenetic checks and balances followed by unscheduled shut-off of tumor-suppressor genes and switch-on of genes that promote cell proliferation.
  • 1st generation of anti-cancer epigenetic drugs are significantly flawed by their (i) relatively low potency and (ii) poor selectivity. e.g. the inhibitors hit also multiple deacetylases of non-histone proteins which are essential for proper functioning of normal cells. Thus, 1st generation epigenetic drugs are relatively toxic and could be prescribed only for a limited number of malignant indications.

Our Innovation

The  researchers synthesized small molecules having dual enzyme inhibition activity. The novel dual- specificity epigenetic drugs target simultaneously two key enzyme families reaching two major advantages:

  • Higher potency
  • Better selectivity for cancer cells

Opportunity

  • Treatment of various types of cancer such as Lung cancer, pancreatic cancers, colon cancers, gastric cancer, liver cancer, myeloid leukemia, melanomas, breast cancer
  • Treatment of epigenetic related diseases such as osteoarthritis and Alzheimer's disease.

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608